{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:25:11Z","timestamp":1781234711564,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ejca.2011.01.007","type":"journal-article","created":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T09:25:50Z","timestamp":1298366750000},"page":"1258-1266","source":"Crossref","is-referenced-by-count":46,"title":["Expression of insulin-like growth factor system components in Ewing\u2019s sarcoma and their association with survival"],"prefix":"10.1016","volume":"47","author":[{"given":"Katia","family":"Scotlandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alberghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Magagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Lopez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombard-Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Picci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2011.01.007_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2003.08.022","article-title":"Long-term outcome for patients with non-metastatic Ewing\u2019s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992","volume":"40","author":"Bacci","year":"2004","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2011.01.007_b0010","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2011.01.007_b0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11864-009-0104-6","article-title":"Ewing\u2019s sarcoma: standard and experimental treatment options","volume":"10","author":"Subbiah","year":"2009","journal-title":"Curr Treat Options Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2011.01.007_b0020","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1158\/0008-5472.CAN-08-4041","article-title":"Advances in Ewing\u2019s sarcoma research: where are we now and what lies ahead?","volume":"69","author":"Ordonez","year":"2009","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.ejca.2011.01.007_b0025","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1002\/cncr.24458","article-title":"Bone and soft tissue sarcomas are often curable\u2013but at what cost?: a call to arms (and legs)","volume":"115","author":"Barr","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2011.01.007_b0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1470-2045(07)70169-9","article-title":"Opportunities for improving the therapeutic ratio for patients with sarcoma","volume":"8","author":"Wunder","year":"2007","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2011.01.007_b0035","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1349-7006.2009.01232.x","article-title":"Molecular genetics of sarcomas: applications to diagnoses and therapy","volume":"100","author":"Toguchida","year":"2009","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.ejca.2011.01.007_b0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.seminoncol.2009.06.006","article-title":"Small round cell sarcomas","volume":"36","author":"Lessnick","year":"2009","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2011.01.007_b0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/CCO.0b013e328302edab","article-title":"Targeting insulin-like growth factor 1 receptor in sarcomas","volume":"20","author":"Scotlandi","year":"2008","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2011.01.007_b0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/PPO.0b013e3181dbebf9","article-title":"Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside","volume":"16","author":"Olmos","year":"2010","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.ejca.2011.01.007_b0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1470-2045(09)70354-7","article-title":"Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing\u2019s sarcoma: a phase 1 expansion cohort study","volume":"11","author":"Olmos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2011.01.007_b0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/er.2006-0001","article-title":"The role of the IGF system in cancer growth and metastasis: overview and recent insights","volume":"28","author":"Samani","year":"2007","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ejca.2011.01.007_b0065","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.coph.2008.07.004","article-title":"Targeting insulin and insulin-like growth factor signalling in oncology","volume":"8","author":"Pollak","year":"2008","journal-title":"Curr Opin Pharmacol"},{"issue":"20","key":"10.1016\/j.ejca.2011.01.007_b0070","first-page":"4570","article-title":"Insulin-like growth factor I receptor-mediated circuit in Ewing\u2019s sarcoma\/peripheral neuroectodermal tumor: a possible therapeutic target","volume":"56","author":"Scotlandi","year":"1996","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2011.01.007_b0075","doi-asserted-by":"crossref","first-page":"e2634","DOI":"10.1371\/journal.pone.0002634","article-title":"IGF1 is a common target gene of Ewing\u2019s sarcoma fusion proteins in mesenchymal progenitor cells","volume":"3","author":"Cironi","year":"2008","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejca.2011.01.007_b0080","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/er.2008-0047","article-title":"Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease","volume":"30","author":"Belfiore","year":"2009","journal-title":"Endocr Rev"},{"issue":"24","key":"10.1016\/j.ejca.2011.01.007_b0085","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1073\/pnas.0914076107","article-title":"Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy","volume":"107","author":"Ulanet","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.ejca.2011.01.007_b0090","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1535-7163.MCT-10-0318","article-title":"Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer","volume":"9","author":"Buck","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.ejca.2011.01.007_b0095","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1248\/bpb.25.991","article-title":"Detection of chimeric genes in Ewing\u2019s sarcoma and its clinical applications","volume":"25","author":"Kojima","year":"2002","journal-title":"Biol Pharm Bull"},{"issue":"11","key":"10.1016\/j.ejca.2011.01.007_b0100","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/1097-0142(20011201)92:11<2941::AID-CNCR10072>3.0.CO;2-C","article-title":"Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors","volume":"92","author":"Toretsky","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2011.01.007_b0105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/1078-0432.206.11.1","article-title":"Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma","volume":"11","author":"Ahlen","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2011.01.007_b0110","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F","article-title":"Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer","volume":"89","author":"Schnarr","year":"2000","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2011.01.007_b0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-008-0046-x","article-title":"Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics","volume":"115","author":"Mu","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2011.01.007_b0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF02778078","article-title":"Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis","volume":"7","author":"Plymate","year":"1997","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.ejca.2011.01.007_b0125","first-page":"565","article-title":"Insulin receptor expression and clinical outcome in node-negative breast cancer","volume":"109","author":"Mathieu","year":"1997","journal-title":"Proc Assoc Am Physicians"},{"issue":"1","key":"10.1016\/j.ejca.2011.01.007_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-006-9471-x","article-title":"Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer","volume":"106","author":"Mulligan","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.ejca.2011.01.007_b0135","first-page":"1790","article-title":"Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing\u2019s sarcoma cells","volume":"7","author":"Benini","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2011.01.007_b0140","first-page":"325","article-title":"Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol","volume":"8","author":"Beech","year":"2001","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.ejca.2011.01.007_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006208721167","article-title":"Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death\u2013proliferative and anti-apoptotic effects","volume":"56","author":"Gooch","year":"1999","journal-title":"Breast Cancer Res Treat"},{"issue":"49","key":"10.1016\/j.ejca.2011.01.007_b0150","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1038\/sj.onc.1203854","article-title":"The contradictions of the insulin-like growth factor 1 receptor","volume":"19","author":"Baserga","year":"2000","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ejca.2011.01.007_b0155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccr.2007.02.027","article-title":"Mesenchymal stem cell features of Ewing tumors","volume":"11","author":"Tirode","year":"2007","journal-title":"Cancer Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T10:11:57Z","timestamp":1685959917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0959804911000311"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.01.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}